SGLT2 inhibitors were shown to lower HbA1c and insulin dosage in diabetes mellitus patients without a significant risk of hypoglycemia by Yang et al., suggesting that insulin resistance is improving [45]. This evidence concerns the gene SLC5A2 and diabetes mellitus.